The major hospitals S University Main Hospital and C University S St. Mary's Hospital, along with the top private university hospital K University A Hospital, applied as a multi-center consortium for the Korea Health Industry Development Institute's User Clinical Evaluation Support Project but were not selected.

Despite the difficult circumstances caused by the medical crisis, we decided to conduct a user clinical evaluation using a cylinder pump that overcomes the fundamental and structurally serious safety and reliability issues of existing drug infusion pumps. This evaluation will take place in the intensive care units of S University Main Hospital, K University A Hospital, and Y University Wonju C Hospital, excluding C University S St. Mary's Hospital. Through this evaluation, we aim to confirm competitiveness and publish a reference paper on efficacy. This will establish a foundation for replacing existing products not only at the evaluating hospitals but also at other domestic hospitals, and provide evidence for entering the US and advanced markets.

Although an upgrade to a model suitable for the relevant department is needed, we plan to list it based on the user clinical evaluation already completed at the major S University SS Hospital and the upcoming user clinical evaluations at major and key hospitals. On March 29th at the Seoul Dragon City Hospital Critical Care Nurses Association Gold Zone booth and April 24th-25th at the Coex Korean Society of Critical Care Medicine booth, alongside the approved Rack, we promoted the cylinder pump—the ultimate version of the drug infusion pump—to expand listing to national university hospitals. We increased usage through reorders from already listed hospitals. Company N in the US will develop a dedicated CSTD for Anyfusion ACPi Pro, along with a 5,000cc/hr cartridge and various Anyfusion ACPi Pro equipment suitable for all hospitals worldwide. This will enable blockbuster-level sales in the global market within a short period. We will maximize sales in 2025 and 2026 to pursue a normal IPO while simultaneously advancing the technology evaluation for a technology-based listing.

Thank you.